A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma

This study is testing a new experimental treatment called RZ-001 in combination with two existing drugs (valganciclovir and atezolizumab/bevacizumab) for patients with hepatocellular carcinoma (primary liver cancer) at an intermediate to advanced stage. RZ-001 is a cancer vaccine approach that targets a protein called hTERT, which is overexpressed in many cancers. **You may be eligible if...** - You are an adult (male or female) - You have been diagnosed with hepatocellular carcinoma at BCLC stage B or C (intermediate or advanced) - Your tumor tests positive for the hTERT protein - Your performance status is 0 or 1 (able to carry out daily activities with little or no restriction) - Your liver function is well-preserved (Child-Pugh score A) - Your life expectancy is at least 3 months **You may NOT be eligible if...** - You have moderate or severe fluid buildup in your abdomen (ascites) - You have a history of hepatic encephalopathy (brain dysfunction related to liver disease) - You have other types of cancer besides HCC - You are HIV-positive - Your doctor does not consider you suitable for the study Talk to your doctor to see if this trial is right for you.